Table 1.
Key Baseline Characteristics of Participants in Studies 1, 2, and 3.
| Study 1[2] N = 309a | Study 2[9] N = 344 | Study 3[19] N = 625 | |
|---|---|---|---|
| Women, n (%) | 222 (73) | 194 (56) | 424 (68) |
| Age, years | 82 ± 10b | 81 (56 –97)c | 83 ± 8d |
| White | 299 (98) | 547 (99) | 554 (89) |
| Alzheimer’s dementia, n (%) | 180 (59) | 229 (67) | 456 (73) |
| Vascular dementia, n (%) | 88 | 90 (26) | 97 (16) |
| Mixed dementia, n (%) | 41 | 25 (7) | 72 (12) |
| MMSE, total score | 5.5 ± 8.0b | 8.4e | 6.6 ± 6.3d |
CI, confidence interval; MMSE, Mini Mental State Exam; SD, standard deviation; SEM, standard error of the mean.
a
A total of 345 patients were randomized, 337 included at least 1 dose of study drug, and baseline characteristics were calculated for patients from included sites only.
b
Mean ± SD (estimated based on mean and SEM values for each group)
c
Median (range)
d
Mean ± SD
e
Mean (original paper cites 95 % Cis for each treatment group, which we did not consider informative enough to provide data spread estimate for the total sample)